GENova appoints Dr. Philip Gould to Scientific Advisory Board

GENova appoints Dr. Philip Gould to Scientific Advisory Board

NEW YORK, NY, Sept. 13 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova
Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies,
acquires, and develops novel drug targets that disrupt the advance of
life-threatening diseases,  today announced it has appointed Dr. Philip Gould
as a Member Designate of its Scientific Advisory Board (SAB).
Dr. Gould will contribute his career experience in multinational blue chip
drug discovery companies as well as his drug patenting experience to GENova's
business of identifying, evaluating and developing pioneering research drugs
Aaron Whiteman, CEO of GENova, says, "Mr. Gould's esteemed position as an
international business leader in the healthcare and drug development sectors
is an asset to GENova."

About Dr. Philip Gould

Mr. Gould is presently the Chief Business Officer of the Liverpool School of
Tropical Medicine, the first institution of its kind dedicated to research in
tropical medicine. He also maintains his position as Founder and CEO of Jadara
Pharma Ltd, a profitable healthcare business consultancy with contracts in
strategic business planning, fund raising, patent litigation, strategic
product development, spin out portfolio management and investor support to
trade sale or IPO. Previously, he was CEO of Provalis plc, a pharmaceutical
and medical diagnostics company. Other positions have included Principle
Research Scientist and Senior Manager of Pharmaceutical Development for
Pfizer, and Head of New Product Development for GlaxoSmithKline.
He has produced over 20 publications as a primary author,  and has presented
25 papers at seminars on a variety of both technical and managerial subjects,
and has been named  as an  inventor on 4 patents. He holds a Ph.D in Physical
Chemistry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the
development and commercial licensing of novel therapeutic proteins that
disrupt the advance of life-threatening cancers. The company leverages
cutting-edge research collaborations to achieve breakthroughs in anti-cancer
treatments, and then licenses these patented drug product candidates to Big
Pharmaceutical and Biotechnology companies such as Pfizer (NYSE: PFE), Amgen
(Nasdaq: AMGN), Myriad Genetics (Nasdaq: MYGN), Medarex (Nasdaq: MEDX), and
Biogen Idec (Nasdaq: BIIB) . Visit GENova online at www.genovabio.com

Forward Looking Statements

This document includes certain statements that may be deemed to be
"forward-looking statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. All statements, other than statements of
historical fact, are expected by the Company to be forward-looking statements.
Although GENova believes the expectations expressed in such forward-looking
statements are based on reasonable assumptions, such statements are not
guarantees of future performance and actual results or developments may differ
materially from those in the forward-looking statements. Factors that could
cause actual results to differ materially from those in forward-looking
statements include but are not limited to the success of the owned
intellectual property, the strength of the patents, continued availability of
capital and financing, and general economic market or business conditions.
SOURCE  GENova Biotherapeutics, Inc.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.